CASI pharmaceuticals
As of the edition of 20 October 2026, CASI pharmaceuticals runs 4 drugs; it is on route A at 20 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- CASI pharmaceuticals, Inc.: renamed in 2023
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 3 |
| Total | 4 |
Where it needs a new molecule
Route A at 20 targets, route B at 0 targets.
All 20 rows on route A or B
In the product20 company-target rows on route A or B; 17 are not shown here, and no score is.
See all 20 targets where CASI pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 16 trials led
- Blood and lymph: 6 trials led
- Heart and blood vessels: 3 trials led